Hepatitis B News and Research

Latest Hepatitis B News and Research

Interim report from Medivir

Medivir designated another candidate drug (CD), MIV-711 in its osteoporosis portfolio, thus enhancing its commercial opportunities.

21 Oct 2009

Dutch researcher sheds new light on coronaviruses

Using novel techniques, Dutch researcher Matthijs Raaben has cast new light on the replication of coronaviruses, a family of viruses including the cause of SARS. He has shown, using luminescent viruses, how coronaviruses use host cells and how we can use the intracellular processes to attack the virus.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Public health nurses with the Sudbury and District Public Health Unit are going to conciliation in their bid to reach a new contract with their employer. Conciliation dates have been set for November 3 and 4, 2009.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Celsion Corporation announced today that it has received approval from the regulatory agencis in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

Roundtable discussion to elevate awareness about the importance of biopreparedness

Emergent BioSolutions Inc. was pleased to sponsor the Security and Defence Agenda’s (SDA) roundtable discussion, “Raising Biopreparedness Levels in Europe,” which examined European efforts in preparing and reacting to various biological threats and the potential for European cooperation in these areas.

19 Oct 2009

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Celsion Corporation announced today that it has received official approval from China’s State Food and Drug Administration (“SFDA”) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).

15 Oct 2009

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).

15 Oct 2009

Hepatitis B News and Research

Latest Hepatitis B News and Research

Interim report from Medivir

Dutch researcher sheds new light on coronaviruses

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Patients with chronic hepatitis C can benefit by drinking coffee

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Biomagnetics Diagnostics to raise $1 million

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Cangene to acquire U.S. commercialization rights for HepaGam B

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Rituxan's sBLA receives a Complete Response from the FDA

Roundtable discussion to elevate awareness about the importance of biopreparedness

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in